GlassScriptPhysician profile
Sijan Basnet
NPI 1386097202
$5,868.75
in general payments reported to CMS, 2019-2025
15 companies · $3,852 in 2025
The $3,852 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $975 · 2024: $1,042 · 2025: $3,852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,291 · Travel and Lodging: $866 · Education: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,290.55 |
| Travel and Lodging | $865.81 |
| Education | $712.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,434.05 | 2025 | Venaseal, Corevalve Evolut R |
| Abbott Laboratories | $1,409.27 | 2023-2025 | Ensite, Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Pfizer INC. | $828.69 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $552.96 | 2023-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $423.61 | 2023-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $360.54 | 2023-2024 | Xarelto, Invega Sustenna |
| Scpharmaceuticals INC. | $286.34 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $195.86 | 2023-2025 | Lokelma, Farxiga, Brilinta |
| Impulse Dynamics (USA) INC. | $179.75 | 2025 | Optimizer |
| Novartis Pharmaceuticals Corporation | $85.53 | 2025 | |
| Mannkind Corporation | $27.97 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $26.63 | 2024 | Arcalyst |
| Lantheus Medical Imaging, INC. | $22.25 | 2025 | |
| Edwards Lifesciences Corporation | $21.06 | 2023 | Sapien 3 Ultra Resilia |
| Inspire Medical Systems, INC. | $14.24 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sijan Basnet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.